Opportunistic Infections, References

Specific References

1. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions J Antimicrob Chemother. 2006; 57:167-70

2. Meintjes G, Stek C, Blumenthal L, et al.; PredART Trial Team. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
N Engl J Med. 2018; 379:1915-1925

3. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010; 24:2381-90

4. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009; 48:e96–107

5. Hakim J, Musiime V, Szubert AJ et al for the REALITY Trial Team. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV
Infection in Africa.N Engl J Med. 2017 Jul 20;377(3):233-245

6. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018 Mar 15;378(11):1004-1017

7. Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, Tam VV, Thanh NT, Thuy TP, Hang
NT, Long HB, Nhan HT, Wertheim HFL, Merson L, Shikuma C, Day JN, Chau NVV, Farrar J, Thwaites G, Wolbers M; IVAP Investigators. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. N Engl J Med 2017;376(24):2329-40

8. Ferretti F, Bestetti A, Yiannoutsos CT, et al. Diagnostic and prognostic value of JC virus DNA in plasma in Progressive Multifocal Leukoen-cephalopathy. Clin Infect Dis. 2018 Jan 15. doi: 10.1093/cid/ciy030

9. Nahid P, Dorman SE, Alipanah N et al. Official American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016; 63:e147-95

10. Gopalan N, Santhanakrishnan RK, Palaniappan AN,et al. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial. JAMA Intern Med. 2018. Apr 1;178(4):485-493

11. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a
systematic review and meta-analysis. Lancet Infect Dis. 2016 Nov 16. pii: S1473-3099(16)30407-8

12. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf

13. Aung, K. J. M., Van Deun, A., Declercq, E., Sarker, M. R., Das, P. K., Hossain, M. A., Rieder, H. L. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. Volume 18, Number 10, 1 October 2014, pp. 1180-1187(8)

14. A.J. Nunn, P.P.J. Phillips, S.K. Meredith, C.-Y. Chiang, F. Conradie, D. Dalai, A. van Deun, P.-T. Dat, N. Lan, I. Master, T. Mebrahtu, D. Meressa, R. Moodliar, N. Ngubane, K. Sanders, S.B. Squire, G. Torrea, B. Tsogt, and I.D. Rusen, for the STREAM Study Collaborators. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. NEJM, March 13, 2019. DOI: 10.1056/NEJMoa1811867

15. F Conradie, A Diacon, D Everitt, C Mendel, A Crook, P Howell, K Comins, M Spigelman. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid. 49th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), 2018. Abstract OA03-213-25

16. Swindells S, Ramchandani R, Gupta A, et al. BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808

17. BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018 (2019 interim update). https://www.bhiva.org/TB-guidelines

General References

UK: British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individu-als 2011. HIV Medicine (2011), 12 (Suppl. 2), 1-140 (http://www.bhiva.org/OI-guidelines.aspx)

US: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf

France: https://cns.sante.fr/wp-content/uploads/2018/05/experts-vih_infections.pdf

Spain: GESIDA/SEIMC Writing Committee. Recomendaciones de GESIDA sobre el tratamiento de la tuberculosis en adultos infectados por el VIH. Actualización Mayo 2018. http://gesida-seimc.org/wp-content/uploads/2018/08/gesida_TB_en_VIH.pdf

Germany and Austria: Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C; Deutsche AIDS Gesellschaft; Österreichische AIDS-Gesellschaft. Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection. 2013 Sep;41 Suppl 2:S91-115. doi: 10.1007/s15010-013-0504-1. Epub 2013 Sep 14.

Italy: Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2018 Oct;41(4):247-255. http://www.newmicrobiologica.org/PUB/allegati_pdf/2018/4/247.pdf and http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf

Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2016 Nov 16. pii: S1473-3099(16)30407-8

Nahid P, Dorman SE, Alipanah N et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016; 63:e147-95